Q-omics provides the consensus-scored SRP19 profile across patient tissues and cancer cell-line models. SRP19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SRP19 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, SRP19 protein abundance shows 23,157 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, LIHC, and PDAC as cancer lineages where SRP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRP19 survival associations across molecular data types. SRP19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRP19 RNA expression–survival associations across cancer types. High SRP19 expression shows unfavorable associations in KICH, KIRP, ACC, UVM, ESCA and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SRP19 RNA expression.
This table summarizes SRP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SRP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRP19 shows higher tumor expression in LIHC, KIRC, HNSC, STAD, UCEC and BLCA. The LIHC box plot shows higher SRP19 RNA expression in tumor versus normal tissue (log2 FC = +0.866, t-test p < 0.001).
This table shows molecular features associated with SRP19 in patient tissues and cancer cell lines. In patient samples, SRP19 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SRP19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
